

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/141949/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Huang, Juan, Pearson, James Alexander , Wong, F. Susan , Wen, Li and Zhou, Zhiguang 2022. Innate immunity in latent autoimmune diabetes in adults (LADA). *Diabetes/Metabolism Research and Reviews* 38 (1) , e3480. 10.1002/dmrr.3480

Publishers page: <http://dx.doi.org/10.1002/dmrr.3480>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



James Alexander Pearson (Orcid ID: 0000-0002-2867-2269)
Zhiguang Zhou (Orcid ID: 0000-0002-4451-4906)

Innate Immunity in Latent Autoimmune Diabetes in Adults (LADA)

Juan Huang^{1,2}, James Alexander Pearson³, F. Susan Wong³, Li Wen², Zhiguang Zhou^{1*}

1. National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
2. Section of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, Connecticut, USA.
3. Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.

*Corresponding author:

Zhiguang Zhou: Department of Metabolism and Endocrinology, The Second Xiangya Hospital, 139 Renmin Road, Changsha, Hunan 410011, China;

Telephone: +86 731 85292154; *Fax:* +86 731 85367220; *Email:* zhouzhiguang@csu.edu.cn

Abstract

Latent autoimmune diabetes in adults (LADA) is an autoimmune disease that shares some genetic, immunological, and clinical features with both type 1 diabetes and type 2 diabetes. Immune cells including CD4⁺ T cells, CD8⁺ T cells, B cells, macrophages, and dendritic cells (DCs) have been detected in the pancreas of patients with LADA and a rat model of LADA. Therefore, similar to type 1 diabetes, the pathogenesis of LADA may be caused by interactions between islet β -cells and innate and adaptive immune cells. However, the role of the immunity in the initiation and progression of LADA remains largely unknown. In this review, we have summarized the potential roles of innate immunity and immune-modulators in LADA development. Furthermore, we have examined the evidence and discussed potential innate immunological reasons for the slower development of LADA compared with type 1 diabetes. More in-depth mechanistic studies are needed to fully elucidate the roles of innate immune-associated genes, molecules, and cells in their contributions to LADA pathogenesis. Undertaking these studies will greatly enhance the development of new strategies and optimization of current strategies for the diagnosis and treatment of the disease.

Key words: Latent autoimmune diabetes in adults; Innate immunity; Autoimmune; Diabetes mellitus; Innate immune cells.

1. Introduction

Latent autoimmune diabetes in adults (LADA), also known as type 1.5 diabetes or slow-onset diabetes in adults, is an autoimmune disease that shares some genetic, immunological, and clinical features with both type 1 diabetes and type 2 diabetes(1-5). The disease was first described in 1983(6) and was defined as LADA in 1993(7). Although LADA accounts for approximately 1.5%-14.2% of the type 2 diabetes population(8-14), no unified criteria or management guidelines have existed for LADA. Recently, a panel of international experts defined a strategy for LADA management, which will be greatly helpful to the diagnosis and treatment of the disease in clinical practice(15).

GADA level is considered as the most valuable discriminatory parameter to predict the development of β -cell function in LADA(16). Compared with low level of glutamic acid decarboxylase antibody (GADA), high level of GADA in LADA is associated with faster insulin progression, indicating that the presence of high level of GADA was a significant predictor of insulin requirement in LADA(17). Our group also found that patients with high level of GADA showed a worse baseline and accelerated decline of β -cell function(18), while the metabolic phenotypes and β -cell function in LADA patients with a low level of GADA were similar to that in type 2 diabetes patients(19). It was reported that the presence of N-terminally truncated GAD65 autoantibody in individuals with adult-onset diabetes is associated with the clinical phenotype and can predict insulin therapy compared with the presence of full-length GAD65 autoantibody(20). IA-2A presence, in addition to GADA, is also highly predictive of future need for insulin therapy(21). Among seven IA-2 constructs, IA-2(256-760) fragment was identified as a marker with the highest sensitivity for detection of humoral IA-2 immunoreactivity in LADA patients, which is also able to identify IA-2 immunoreactivity among GADA⁻ patients with type 2 diabetes(22).

It is believed that the initiation and progression of autoimmune diabetes, such as type 1 diabetes, involves complicated cross-talk between β -cells and immune cells from both innate and adaptive immune systems(23). In type 1 diabetes, CD8⁺ T cells are the most abundant infiltrating cells in humans, with CD4⁺ T cells, macrophages, and B cells simultaneously

Accepted Article

detected in the inflammatory pancreatic islets(24). In animal models of human type 1 diabetes, dendritic cells (DCs) and neutrophils were also found to infiltrate the islets in the early stage of the disease development(25). Like type 1 diabetes, insulinitis also seems to be the hallmark of the immune-mediated β -cell damage in LADA. The occurrence of insulinitis in LADA was initially confirmed by pancreatic scintigraphy in the pancreata of LADA patients(26), and it was verified in a LADA animal model (a spontaneous rat model of LADA) recently(27). Compared with insulinitis seen in type 1 diabetes, insulinitis in LADA encompasses a changed ratio of tumor necrosis factor- α (TNF- α)/interleukin-1 β (IL-1 β) expression, an increased expression of IL-10, and an increased number of macrophages which predominate in the immune infiltration over CD8⁺ T cells(27) (Figure 1). Apart from immune cell infiltration in islets, LADA patients displayed an altered frequency of B cell subsets, which is closely associated with altered β -cell function(28). Therefore, immunity may play a crucial role in the pathogenesis of LADA. In this review, we summarize the current studies investigating the role of innate immunity in LADA.

2. Genetic studies in LADA patients identify polymorphisms in genes associated with innate immunity

Until now, most genetic studies of LADA have focused on genes relevant to type 1 diabetes (*HLA-DQB1*, *INS*, *PTPN22*, and *CTLA4*) and those associated with type 2 diabetes (*FTO*, *PPARG*, *TCF7L2*, and *SLC30A8*)(29, 30). Recently, Cousminer *et al.* performed the first Genome-Wide Association Study (GWAS) of patients diagnosed with LADA(3). The pathway analysis with DEPICT (an integrative tool that employs predicted gene functions to systematically prioritize the most likely causal genes at associated loci) revealed physiological abnormalities in natural killer (NK) cells, T lymphocytes, mTOR regulatory network, and cell cycle, supporting a strong immune role in the pathogenesis of LADA(3). In this study, it was found that *SH2B3* was also closely associated with the susceptibility to LADA. Moreover, a novel signal at the *PFKFB3* locus that can distinguish LADA from type 1 diabetes and type 2 diabetes was identified, but it needs further validation(3). Apart from the genes mentioned above, other genes that are closely associated with innate immune regulation have also been linked with disease susceptibility to LADA, including major histocompatibility complex class

I (MHC-I) chain-related gene (*MIC-A*), killer cell immunoglobulin-like receptors (*KIRs*), *TNF- α* , and *IL-10*.

2.1. *MIC-A*

Several studies investigated the effects of MHC class region, especially the HLA class II genes *HLA-DRB1* and *HLA-DQB1* in LADA. It was found in the population of European ancestry that *HLA-DRB1*0301(DR3)*, *HLA-DRB1*0401(DR4)*, *HLA-DQB1*0201(DQ2)* and *HLA-DQB1*0302(DQ3)* conferred susceptibility to LADA(31). In Chinese population, *HLA-DRB1-DQA1-DQB1* loci was found to have a close association with LADA susceptibility(32). Additionally, Mishra *et al.* investigated the relation of the MHC class I alleles with LADA, finding that class I genes (*HLA-A* and *HLA-B*) are not associated with LADA(33). *MIC-A* is a polymorphic gene located in the HLA region mainly expressed by monocytes, keratinocytes, and endothelial cells(34). Raache *et al.* found that patients with LADA from an Algerian population, like juvenile type 1 diabetes patients, had an increased frequency of valine at position 129 of *MIC-A* compared to healthy control subjects. This single amino acid change may affect the activation of NK and CD8⁺ T lymphocytes, and thus, alter the risk for autoimmune diabetes(35). Moreover, the combination of the *MIC-A-129 Val/Val* genotype with *DR3-DQ2* or *DR4-DQ8* was found to confer an increased risk for both adult-onset type 1 diabetes and LADA(35). In an Italian population, it was demonstrated that the presence of either *MIC-A5.1* or *MIC-A5* discriminated LADA patients from type 1 diabetes patients(36). *MIC-A5* was found to confer a genetic risk for type 1 diabetes, while *MIC-A5.1* was significantly increased among LADA patients. This was also demonstrated in subjects from Latvia and eastern Indian populations(37, 38); however, Carina *et al.* found that in a Swedish population, *MIC-A5.1* was increased in patients with LADA and type 1 diabetes, while heterozygosity for *MIC-A5/5.1* was the important genotype related to significant risk for LADA(39). Taken together, these studies indicate that *MIC-A5.1* may play an important role in the pathogenesis of slow-onset autoimmunity in LADA through altered activation of NK cells and T cells(36-38). However, Mishra and colleagues' recent report, which studied populations from UK, Germany and USA, showed that the independent effects of MHC class I observed in type 1 diabetes were not observed in LADA after conditioning on the leading

MHC class II associations(33). As these studies are from different populations and the sample size of some was relatively small, therefore, more studies with larger sample size among different populations, are warranted to confirm the role of these genes and the function of the proteins encoded by these genes in the pathogenesis of LADA.

2.2. *KIRs*

KIRs are surface receptors expressed on NK cells that play crucial roles in the innate immune system by mediating the early killing of virally infected cells and tumors(40, 41). MHC molecule recognition by inhibitory KIRs usually leads to the suppression of the cytotoxic activity of NK cells, while the recognition by activatory KIRs can lead to the activation of cytotoxic activity of the cells(42, 43). It was reported that the activating of *KIR-HLA* genes was increased in young children diagnosed with type 1 diabetes in the first 5 years of life, indicating that type 1 diabetes patients may have altered NK cell responses(44). In LADA, *KIR* genes confer susceptibility to, or protection from the disease, and their roles in modulating disease susceptibility or protection are closely associated with the ethnicity of the subjects(45). In a Latvian population, *KIRs* 2DL1, 2DS2, and 2DS4 were all associated with susceptibility to LADA, while *KIR* 2DS5 was associated with protection. However, in an Asian Indian population, the *KIRs* 2DL5 and 3DL1 were associated with the susceptibility to LADA, and 2DS1 and 2DS3 were associated with protection(45).

2.3. *TNF- α* and *IL-10*

Cytokine gene polymorphisms may also contribute to the pathogenesis of LADA. *TNF* genes have a strong linkage disequilibrium with *HLA* class I/II genes and other *MHC* genes associated with immune-regulation(46). *TNF- α* , encoded within the *TNF* locus, is released by activated innate immune cells such as monocytes, macrophages, NK cells and adaptive immune cells (T and B cells)(46). Although *TNF- α* -308A/G single nucleotide polymorphisms (SNPs) do not contribute to the development of LADA(47), it was found that homozygosity for *TNF- α* -308A/A (*TNFA2/2*) is a risk factor for both LADA and type 1 diabetes(48). The genetic risk associated with *TNFA2/2* is likely to be due to linkage disequilibrium with *HLA-DR3-DQ2* and *DR4-DQ8*(48). IL-10, an anti-inflammatory cytokine, is a major suppressor of the immune system capable of regulating T cell proliferation and downregulating cytokine production from

activated innate (monocytes/ macrophages and DCs) and adaptive (T and B) immune cells(49). Tsiavou *et al.* found that the frequency of 1082*A *IL-10* alleles was increased in LADA patients, compared with individuals with type 2 diabetes, who had 1082*G alleles more frequently(47). This suggests that the A/G mutation at position -1082 of the *IL-10* promoter gene region may be one of the factors participating in the pathogenesis of LADA(47).

3. Innate immune cells in LADA

3.1. Monocytes/Macrophages

Monocytes constitute about 5-10% of circulating leukocytes in human peripheral blood and can be divided into two subsets - classical CD14^{hi}CD16⁻ monocytes and non-classical CD14⁺CD16⁺ monocytes, the latter of which are more mature and resemble tissue macrophages(50). Macrophage can infiltrate the islets, involving in the initiation of the insulinitis, β -cell destruction, and the development of type 1 diabetes(51-53). It was reported that resident macrophages in pancreatic islets can also initiate type 1 diabetes(54) and contribute to the inflammation affecting β -cell function in obesity(55). Several studies have shown that individuals with type 1 diabetes had increased monocytic activity compared with control individuals(56-59). Investigation of CD14⁺ monocytes revealed altered gene expression between patients with LADA, juvenile-onset type 1 diabetes, adult-onset type 1 diabetes, type 2 diabetes, and healthy control subjects(60). Interestingly, CD14⁺ monocytes from LADA and adult-onset type 1 diabetes patients showed similar immune characteristics distinct from juvenile-onset type 1 diabetes(60). No significant alterations were found in the proportions of CD16⁺ monocytes in LADA patients when compared with healthy controls or patients with type 1 diabetes or type 2 diabetes(61) (Table 1); however, Pavlina *et al.* found that patients who had autoimmune diabetes, including patients with LADA and type 1 diabetes, had lower counts of CD14^{hi}CD16⁻ monocytes and CD14^{lo}CD16⁺ monocytes than healthy control subjects(62). Additionally, CD68⁺ macrophages, together with CD8⁺ T cells, were found to infiltrate the pancreatic islets in LADA patients(63). Recently, Jörns and colleagues have confirmed the pancreatic infiltration of macrophages and CD8⁺ T cells in LADA by investigating the pancreata from LADA patients and a rat model of LADA(27). Here, the authors found that there was an increased ratio of macrophages to CD8⁺ T cells in the pancreata of LADA when compared with macrophage/CD8⁺ T cell from the pancreata of type 1 diabetes.

Accepted Article

It was documented that macrophages can produce more IL-1 β than other types of immune cells(64), and β -cell destruction may be induced by interleukin 1 β (IL-1 β) released from activated monocytes/macrophages(51, 65). Jörns *et al.* found that LADA pancreas displayed a predominance of IL-1 β in the infiltrated immune cells compared with the predominance of TNF- α found in the immune cell in the pancreas of type 1 diabetes. Although it is unclear whether the source of increased IL-1 β is from macrophages or not in LADA pancreas, it was considered that increased IL-1 β can recruit more macrophages to the islets to remove the apoptotic β -cells, which might be a major reason why LADA develops slower than type 1 diabetes(27).

3.2. Dendritic cells

Studies from both humans and animal models have shown that dendritic cells (DCs) are major players in modulating the development of type 1 diabetes by promoting the islet autoantigen presentation to T-cells, augmenting Th1 responses, or mediating the tolerance of autoreactive CD4⁺ T cells(66-70). DCs, together with macrophages, were reported to infiltrate the pancreatic islets and activate CD4⁺ T cells via IL-12 secretion(71). To date, few studies have investigated the importance of DCs in LADA. In 2009, Kelly and colleagues compared the phenotype of DCs in LADA patients with that in subjects with type 1 diabetes and healthy control individuals, with DCs defined as HLA-DR⁺ cells that were deficient in lineage-specific markers (CD3, CD14, CD16, CD19, and CD57). Unlike monocyte-derived DCs, which showed both phenotypic and functional changes in patients with type 1 diabetes(72), the total number of DCs and the proportions of myeloid DC (CD11c⁺) and lymphoid DC (CD11c⁻) subsets were similar among patients with LADA, type 1 diabetes and control subjects(73). In addition, Kailash and colleagues also studied DC subsets, including the CD123⁻CD11c⁺, CD123⁺CD11c⁺, and CD123⁺CD11c⁻ plasmacytoid dendritic cells (pDCs) subsets, in healthy controls and patients with LADA, type 1 diabetes, and type 2 diabetes(61). In this study, no significant differences were found in the proportions of pDCs between the four groups; however, patients with LADA had a lower proportion of CD123⁻CD11c⁺ DCs compared to patients with type 1 diabetes(61). As CD123⁻CD11c⁺ DCs may prime T cells to target the insulin-producing β -cells(61), the decreased numbers of CD123⁻CD11c⁺ DCs found in patients

with LADA may provide further evidence of why the immune response is reduced and progression of β -cell failure is slower in LADA patients than type 1 diabetes patients(61).

3.3. Natural killer cells

The role of natural killer (NK) cells in type 1 diabetes development is unclear, and the studies regarding NK cell infiltration in islets of patients are inconsistent, with some reporting NK cell infiltrates(74) and others reporting no NK cell infiltration(75). Recently, NK cells were detected within the pancreatic islet of individuals and rats with LADA, representing approximately 10% of the islet immune cell infiltrated(27). Additionally, Akesson *et al.* showed that Caucasian patients who have LADA diagnosed within 5 years had a significant decrease in CD3⁺CD56⁺ NK cell frequency in the peripheral blood compared to healthy individuals(76). In contrast, newly diagnosed Caucasian patients with LADA showed a higher proportion of CD3⁺CD56^{high}CD16⁺ NK cells than both healthy controls and patients with type 2 diabetes(61). In a Chinese population, it was found that patients diagnosed with LADA within one month had a higher frequency of CD3⁺CD56⁺ NK cells, activated NKp46⁺ NK cells, and interferon (IFN)- γ ⁺ NK cells, but lower 3DL1⁺ (a KIR) NK cells than healthy control individuals(77). Moreover, the percentages of circulating NKp46⁺CD3⁺CD56⁺ NK cells were negatively correlated with the levels of fasting plasma C-peptide. These studies have identified differences in NK cells; however, this may result from the varying disease duration of the patients studied. It is possible that an increased frequency of NK cells may be associated with the early stages of the pathogenic process underlying LADA development(77). Except for the KIRs mentioned above, a variety of receptors including NKp30, NKp46, NKG2D, the leukocyte immunoglobulin-like receptors (LIRs), and the CD94/NKG2A heterodimers are also found on NK cells(40, 41). Interestingly, patients with LADA displayed increased expression of activating NKG2D(76) and NKp46(77), but decreased inhibitory 3DL1 expression(76), indicating that the altered activation of NK cells may contribute to the development of LADA. Unlike patients with LADA, the NK cells in both type 1 diabetes patients(78) and the non-obese diabetic (NOD) mouse model of type 1 diabetes(79) display reduced NKG2D expression. Therefore, the higher expression of NKG2D receptor may correlate with the slower progression of β -cell failure in LADA(76). Although a variety of studies have been performed to investigate

the frequency of NK cell subsets and their receptor expression in patients with LADA, the function of NK cells in patients with LADA and their cross-talk with other immune cells such as DCs and CD4⁺CD25⁺ regulatory T cells have not been studied and need to be elucidated in the future.

3.4. Neutrophils

Although autoimmune type 1 diabetes is an organ-specific autoimmune disease mediated primarily by auto-reactive T cells, neutrophils are found to be involved in the early development of the disease by activating plasmacytoid DCs (pDC) to produce IFN- α together with B-1a cells (25, 80). Moreover, numerous studies in patients with type 1 diabetes have shown a decreased number of neutrophils in the circulation(81-84). In patients with LADA, Singh *et al.* found no alteration in the proportions of CD15^{low} neutrophils in the patients with a mean disease duration of close to 5 years(61). We recently found higher numbers of neutrophils in the circulation of newly diagnosed LADA patients (diagnosed within one year) compared to patients with type 1 diabetes(85). However, patients with LADA in our study have lower circulating neutrophil counts compared to patients diagnosed with type 2 diabetes within one year(85). Interestingly, the neutrophil counts in patients with type 1 diabetes or LADA were negatively correlated with the levels of GAD, IA2, and ZnT8 autoantibody. This was particularly evident in those individuals who were positive for all three autoantibodies, which had the lowest neutrophil counts, indicating that neutrophils are associated with the severity of the underlying autoimmune process and β -cell damage in the development of autoimmune diabetes including LADA. Moreover, neutrophils from patients with type 1 diabetes or LADA had impaired migratory ability when compared to either healthy controls or individuals with type 2 diabetes(85). By performing RNA sequencing (RNA-seq) analysis of peripheral blood immune cells, Wang *et al.* found that patients with LADA exhibited 277 differentially expressed genes (DEGs) compared to healthy controls. Further gene ontology (GO) analysis of these DEGs indicated that many of the enriched GO terms were closely related to immune functions, including positive regulation of neutrophil chemotaxis(86). Therefore, increased expression of neutrophil chemo-attractants may also contribute to the augmented inflammation observed in LADA(86). Recently, our group did RNA-seq using isolated neutrophils from

LADA patients and healthy controls, finding that differentially expressed genes between LADA and healthy controls are mainly involved in leukocyte degranulation, myeloid cell differentiation, and immune response-regulating signaling, revealing an abnormality in neutrophil disposition at the transcriptional level in LADA(87).

4. Mechanisms of innate immune activation in LADA

4.1. Toll-like receptors

Toll-like receptors (TLRs) are important pattern recognition receptors, which are widely expressed by various immune cells including monocytes, macrophages, DCs, B cells, T cells, as well as non-immune cells(88). Until now, thirteen mouse TLRs (TLR1-13) and ten human TLRs (TLR1-10) have been identified. Several TLRs including TLR2, TLR3, TLR4, TLR5, TLR7, TLR8, and TLR9 have been demonstrated to play important roles in the development of type 1 diabetes(89-91). However, only TLR2 and TLR4 expression on monocytes have been investigated in LADA. TLR2 and TLR4 can be activated by recognition of lipoteichoic acid (LTA) from Gram-positive bacteria, and lipopolysaccharide (LPS) from Gram-negative bacteria, respectively(92, 93). Our previous study found that LADA patients from a Chinese population had higher expression of TLR4, but not TLR2, on the surface of freshly isolated CD14⁺ peripheral monocytes when compared to patients with type 1 diabetes(94). However, monocytes from patients with LADA or type 1 diabetes exhibited increased reactivity towards LPS and LTA *in vitro*, suggesting that tolerance to LPS and LTA could be dysregulated in both type 1 diabetes and LADA. Therefore, the increased proinflammatory monocyte responses to microbial components are likely to contribute to the pathogenesis of autoimmune diabetes(94).

4.2. NOD-like receptors

Nucleotide oligomerization domain (NOD)-like receptors (NLRs) are another important class of pattern recognition receptors, which can detect microbial components in the cytosol(95). NLRs are also expressed in many cell types including both immune and non-immune cells e.g. epithelial cells. There are 23 NLR family members in humans and at least 34 NLR genes in mice(96). Both Nod1 and Nod2 are important NLRs, which upon recognition of their microbial ligand, can activate NF- κ B and MAPKs to induce an immune response(95, 97). NLRP1, NLRP3, NLRC4, and NLRP6 proteins can form multi-protein complexes called

inflammasomes, which, when activated, play an essential role in caspase-1 activation and the subsequent release of proinflammatory cytokines such as IL-1 β and IL-18(95). Importantly, NOD2 can modulate type 1 diabetes susceptibility by altering the microbial composition, which in turn affects the phenotype and functions of T cells and B cells in the NOD mouse model(98). In addition, in the NOD mouse, NLRP3 also alters susceptibility to type 1 diabetes by limiting the recruitment and infiltration of autoreactive CD4⁺ T cells into the pancreas(99). However, the role of NLRs and inflammasome proteins in the pathogenesis of LADA has not yet been studied and should be investigated in the future.

4.3. Gut microbiota

TLRs, NLRs, and inflammasomes can be activated by microbial components and thus the composition of the microbiota may also alter the signaling of these molecules. Accumulating evidence has shown that gut microbiota play critical roles in the development, education, and function of innate and adaptive immune cells(100, 101). Furthermore, as an environmental factor, the gut microbiota, through interactions with the immune system, have been shown to modulate susceptibility to type 1 diabetes and the altered gut microbiota have been documented to contribute to the increased incidence of type 1 diabetes(102, 103). In 2008, it was firstly demonstrated that gut microbiota modulates type 1 diabetes development in NOD mice via the innate immune system(104). Since then, much research has been focused on the elucidation of the interaction between the host and the gut microbiome in health and disease. Our recent observations have identified that gut microbiota might contribute to the development of type 1 diabetes via modulation of neutrophil homeostasis (Huang *et al.* unpublished). Additionally, increasing evidence has shown that the composition of gut microbiota is altered during the development of type 1 diabetes, exhibiting a less diverse and less stable gut microbiome compared to healthy controls(105, 106). Furthermore, in individuals with type 1 diabetes, there are alterations in the ratio of *Firmicutes* to *Bacteroidetes* compared to healthy controls(105, 107, 108). Increasing evidence demonstrated that the changes in the microbiome might cause islet cell autoimmunity. Studies from human beings showed that the fecal microbiota of individuals with multiple islet autoantibodies displayed distinct bacterial diversity compared with the control subjects(105, 108, 109). Recently, it was found that the intestinal activation of

islet-reactive T cells requires the presence of gut microbiota and is abolished when mice are depleted of endogenous commensal microbiota by antibiotic treatment(110). However, to our knowledge, nothing is known about the gut microbiota composition in patients with LADA and the contribution of the gut microbiota to modulating LADA pathogenesis. This area of investigation would make an interesting future direction for LADA studies.

4.4. Cytokines

Cytokines are important regulators of both innate and adaptive immunity and contribute to the immune-mediated β -cell destruction observed in the development of type 1 diabetes(111, 112). Recently, Jorns *et al.* detected *TNF- α* and *IL-1 β* gene expression in the pancreata of patients and rats with LADA, finding that there was a shift in the proinflammatory cytokine gene expression from *TNF- α* to *IL-1 β* in the pancreata from LADA compared to that from type 1 diabetes (27). Additionally, other cytokines, such as IFN- γ , IL-6, and IL-15, may also contribute to the pathogenesis of LADA. Wang *et al.* detected that newly diagnosed LADA patients had higher percentages of inducible IFN- γ^+ NK cells and NKp46 $^+$ cells than control subjects(77). As NK cells were recently identified in the pancreatic infiltrate of patients and rats with LADA(27), it is possible that IFN- γ secreted from NK cells may alter the insulin-producing β -cells and promote the development of LADA(77). Schloot *et al.* investigated the differences in systemic immune mediators between patients with type 2 diabetes and adult-onset autoimmune type 1 diabetes who had high GADA concentrations or low GADA concentrations (including classic adult-onset type 1 diabetes and LADA). In this study, they found no significant differences in the cytokines, including IL-10, TNF- α , C-C motif chemokine ligand (CCL)-2, CCL3, CCL4, soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular cell adhesion molecule-1 (sVCAM-1) between adult-onset autoimmune type 1 diabetes and patients with type 2 diabetes, but it was observed that type 1 diabetes patients with high GADA level had lower concentrations of IL-6 and soluble E-Selectin compared with patients with type 2 diabetes(113). However, several studies demonstrated that the circulating IL-6 concentration is significantly higher in both patients with LADA and their healthy first-degree relatives compared to healthy control subjects, supporting the pro-inflammatory role for this cytokine in mediating susceptibility to LADA(114-116). For

IL-15, it was found that patients with LADA or type 1 diabetes had a higher level of IL-15 than both control subjects and their first-degree relatives, with relatives having positive autoantibodies showed a higher level of circulating IL-15 than those without autoantibodies(114). Moreover, the concentration of IL-15 is positively correlated with homeostatic model assessment-insulin resistance (HOMA-IR) in LADA and type 1 diabetes, and negatively correlated with estimated glucose disposal rate (eGDR) in LADA, suggesting that IL-15 is potentially a biomarker of the ongoing autoimmune process in humans, particularly in those with LADA(114).

4.5. Chemokines

Chemokines, also called chemotactic cytokines, play essential roles in attracting leukocytes to tissues during inflammation(117). Over 40 chemokines have been identified, and are subdivided into families based on the relative position of their cysteine residues, including α -chemokines (cysteine-X amino acid-cysteine, or CXC) and β -chemokines (cysteine-cysteine, or CC)(118). Previous studies have shown that the serum concentrations of CCL2 and CCL4 did not differ between patients with type 1 diabetes or LADA(113, 119), whereas CCL3 levels were higher in patients with LADA and type 1 diabetes, compared to those with type 2 diabetes and controls(119). By performing RNA-seq analysis from PBMCs of patients with LADA and healthy control subjects, Ji *et al.* found that gene expression levels of chemokine ligands including *CXCL8*, *CCL2*, and *CCL23* were upregulated in patients with LADA(86). It is known that *CXCL8* was originally identified as a potent neutrophil chemotactic factor(120), and both *CCL2* and *CCL23* are potent chemo-attractants for monocytes(121). Therefore, the increased expression of these chemo-attractants for neutrophils and monocytes may contribute to the augmented pancreatic inflammation in LADA(86).

5. Therapeutic approaches targeting innate immunity may be efficacious in LADA

The current approaches for the treatment of patients with LADA include insulin sensitizers, insulin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists, and GAD-alum(15). DPP-4, a serine peptidase also known as CD26, is a cell surface antigen (DPP-4/CD26) expressed on T and B lymphocytes, macrophages, NK cells and acinar, endothelial,

and epithelial cells(122). 1,25(OH)₂D₃, the active form of vitamin D, is an immunomodulator targeting various immune cells including monocytes, macrophages, DCs, as well as T cells, and B cells(123). Therefore, both DPP-4 inhibitors and vitamin D₃ can have substantial effects on the immune system. Prospective studies from our groups(124-126) and post hoc analysis by Buzzetti *et al.*(127) have shown that DPP-4 inhibitors and/or vitamin D₃ benefit patients with LADA by preserving pancreatic reserves, as indicated by higher C-peptide secretion, after treatment. The exploratory analysis by Johansen *et al.* also showed that linagliptin treatment may attenuate the rate of decline in C-peptide levels compared with glimepiride treatment in LADA patients, which may act through elevating the level of endogenous glucagon-like peptide 1 (GLP-1) and/or modulating peptides involved in cell signaling and autoimmunological pathways(128). Combination therapy with DPP-4 inhibitors and vitamin D₃ are believed to induce immunoregulation and reduce the inflammatory response in autoimmune type 1 diabetes(129). Our previous study found that 1,25(OH)₂D₃-treated monocytes from patients with LADA showed significantly reduced IL-1 β and TNF- α production compared to monocytes cultured with LTA or LPS(94). Similar results were also observed in monocytes from patients with type 1 diabetes and healthy controls(94). Although DPP-4 inhibitors and/or vitamin D₃ can help to preserve pancreatic reserves in LADA patients, their roles in the regulation of immunity remain unclear; thus, more investigations are needed to elucidate the effects of vitamin D₃ and/or DPP-4 inhibitors in immune regulation. Furthermore, understanding which patients should receive therapy and when the therapy should start, in order to elicit the greatest effect, will also need to be studied.

Conclusion

Innate immunity plays a crucial role in the pathogenesis of LADA; however, the specific contribution of the innate immune cells and immune modulators to disease development is largely unknown, and most studies related to LADA lack in-depth mechanistic investigation. The rat model of spontaneous LADA, which also develops insulinitis offers a promising tool for the mechanistic investigation. This will greatly help us to better understand LADA pathogenesis with more details, and also offering a model for pre-clinical studies of LADA, which will provide new insights into the diagnosis and treatment of the disease.

Acknowledgements: This work was supported by the National Key R&D Program of China (No. 2016YFC1305000 and No. 2016YFC1305001, to Z.Z.), the National Natural Science Foundation of China (No. 81820108007, to Z.Z.), the Science and Technology Major Project of Hunan Province (No. 2017SK1020, to Z.Z.), and Yale DRC (No. P30 DK045735, to JH).

Author Contributions: J.H. wrote the manuscript. J.P., F.W., and L.W. edited and revised the manuscript. Z.Z. revised the manuscript and provided critical feedback. All the authors approved the final version of the manuscript.

Ethics Statement: Declared none.

Competing interests: The authors have declared that no conflict of interest exists.

Data availability statement: Data sharing is not applicable to this article as no new data were created.

References

1. Juneja R, and Palmer JP. Type 1 1/2 diabetes: myth or reality? *Autoimmunity*. 1999;29(1):65-83.
2. Zimmet P, Turner R, McCarty D, Rowley M, and Mackay I. Crucial points at diagnosis. Type 2 diabetes or slow type 1 diabetes. *Diabetes Care*. 1999;22 Suppl 2:B59-64.
3. Cousminer DL, Ahlqvist E, Mishra R, Andersen MK, Chesi A, Hawa MI, et al. First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes. *Diabetes Care*. 2018;41(11):2396-403.
4. Pozzilli P, and Pieralice S. Latent Autoimmune Diabetes in Adults: Current Status and New Horizons. *Endocrinol Metab (Seoul)*. 2018;33(2):147-59.
5. Buzzetti R, Zampetti S, and Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. *Nat Rev Endocrinol*. 2017;13(11):674-86.
6. Di Mario U, Irvine WJ, Borse DQ, Kyner JL, Weston J, and Galfo C. Immune abnormalities in diabetic patients not requiring insulin at diagnosis. *Diabetologia*. 1983;25(5):392-5.
7. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, and Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. *Diabetes*. 1993;42(2):359-62.
8. Hawa MI, Kolb H, Schloot N, Beyan H, Paschou SA, Buzzetti R, et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. *Diabetes Care*. 2013;36(4):908-13.
9. Sachan A, Zaidi G, Sahu RP, Agrawal S, Colman PG, and Bhatia E. Low prevalence of latent autoimmune diabetes in adults in northern India. *Diabet Med*. 2015;32(6):810-3.
10. Zhou Z, Xiang Y, Ji L, Jia W, Ning G, Huang G, et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. *Diabetes*. 2013;62(2):543-50.
11. Maddaloni E, Lessan N, Al Tikriti A, Buzzetti R, Pozzilli P, and Barakat MT. Latent Autoimmune Diabetes in Adults in the United Arab Emirates: Clinical Features and Factors Related to Insulin-Requirement. *PLoS One*. 2015;10(8):e0131837.
12. Takeda H, Kawasaki E, Shimizu I, Konoue E, Fujiyama M, Murao S, et al. Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study). *Diabetes Care*. 2002;25(6):995-1001.
13. Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI, et al. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. *Diabetes*. 2004;53(12):3193-200.
14. Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. *Diabetes Care*. 2007;30(4):932-8.
15. Buzzetti R, Tuomi T, Mauricio D, Pietropaolo M, Zhou Z, Pozzilli P, et al. Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel. *Diabetes*. 2020;69(10):2037-47.
16. Li X, Chen Y, Xie Y, Xiang Y, Yan X, Huang G, et al. Decline Pattern of Beta-cell

- Function in Adult-onset Latent Autoimmune Diabetes: an 8-year Prospective Study. *J Clin Endocrinol Metab.* 2020;105(7).
17. Zampetti S, Campagna G, Tiberti C, Songini M, Arpi ML, De Simone G, et al. High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7). *Eur J Endocrinol.* 2014;171(6):697-704.
 18. Huang G, Yin M, Xiang Y, Li X, Shen W, Luo S, et al. Persistence of glutamic acid decarboxylase antibody (GADA) is associated with clinical characteristics of latent autoimmune diabetes in adults: a prospective study with 3-year follow-up. *Diabetes Metab Res Rev.* 2016;32(6):615-22.
 19. Liu L, Li X, Xiang Y, Huang G, Lin J, Yang L, et al. Latent autoimmune diabetes in adults with low-titer GAD antibodies: similar disease progression with type 2 diabetes: a nationwide, multicenter prospective study (LADA China Study 3). *Diabetes Care.* 2015;38(1):16-21.
 20. Achenbach P, Hawa MI, Krause S, Lampasona V, Jerram ST, Williams AJK, et al. Autoantibodies to N-terminally truncated GAD improve clinical phenotyping of individuals with adult-onset diabetes: Action LADA 12. *Diabetologia.* 2018;61(7):1644-9.
 21. Bottazzo GF, Bosi E, Cull CA, Bonifacio E, Locatelli M, Zimmet P, et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). *Diabetologia.* 2005;48(4):703-8.
 22. Tiberti C, Giordano C, Locatelli M, Bosi E, Bottazzo GF, Buzzetti R, et al. Identification of tyrosine phosphatase 2(256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2. *Diabetes.* 2008;57(5):1276-83.
 23. Lehuen A, Diana J, Zacccone P, and Cooke A. Immune cell crosstalk in type 1 diabetes. *Nat Rev Immunol.* 2010;10(7):501-13.
 24. Leete P, Willcox A, Krogvold L, Dahl-Jorgensen K, Foulis AK, Richardson SJ, et al. Differential Insulinitic Profiles Determine the Extent of beta-Cell Destruction and the Age at Onset of Type 1 Diabetes. *Diabetes.* 2016;65(5):1362-9.
 25. Diana J, Simoni Y, Furio L, Beaudoin L, Agerberth B, Barrat F, et al. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. *Nat Med.* 2013;19(1):65-73.
 26. Signore A, Capriotti G, Chianelli M, Bonanno E, Galli F, Catalano C, et al. Detection of insulinitis by pancreatic scintigraphy with 99mTc-labeled IL-2 and MRI in patients with LADA (Action LADA 10). *Diabetes Care.* 2015;38(4):652-8.
 27. Jorns A, Wedekind D, Jahne J, and Lenzen S. Pancreas Pathology of Latent Autoimmune Diabetes in Adults (LADA) in Patients and in a LADA Rat Model Compared With Type 1 Diabetes. *Diabetes.* 2020;69(4):624-33.
 28. Deng C, Xiang Y, Tan T, Ren Z, Cao C, Huang G, et al. Altered Peripheral B-Lymphocyte Subsets in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults. *Diabetes Care.* 2016;39(3):434-40.
 29. Chen Y, and Chen G. New genetic characteristics of latent autoimmune diabetes in adults (LADA). *Ann Transl Med.* 2019;7(5):81.
 30. Tuomi T, Santoro N, Caprio S, Cai M, Weng J, and Groop L. The many faces of diabetes: a disease with increasing heterogeneity. *Lancet.* 2014;383(9922):1084-94.

31. Desai M, Zeggini E, Horton VA, Owen KR, Hattersley AT, Levy JC, et al. An association analysis of the HLA gene region in latent autoimmune diabetes in adults. *Diabetologia*. 2007;50(1):68–73.
32. Luo S, Lin J, Xie Z, Xiang Y, Zheng P, Huang G, et al. HLA Genetic Discrepancy Between Latent Autoimmune Diabetes in Adults and Type 1 Diabetes: LADA China Study No. 6. *J Clin Endocrinol Metab*. 2016;101(4):1693–700.
33. Mishra R, Akerlund M, Cousminer DL, Ahlqvist E, Bradfield JP, Chesi A, et al. Genetic Discrimination Between LADA and Childhood-Onset Type 1 Diabetes Within the MHC. *Diabetes Care*. 2020;43(2):418–25.
34. Zwirner NW, Fernandez-Vina MA, and Stastny P. MICA, a new polymorphic HLA-related antigen, is expressed mainly by keratinocytes, endothelial cells, and monocytes. *Immunogenetics*. 1998;47(2):139–48.
35. Raache R, Belanteur K, Amroun H, Benyahia A, Heniche A, Azzouz M, et al. Association of major histocompatibility complex class I chain-related gene a dimorphism with type 1 diabetes and latent autoimmune diabetes in adults in the Algerian population. *Clin Vaccine Immunol*. 2012;19(4):557–61.
36. Gambelunghe G, Ghaderi M, Tortoioli C, Falorni A, Santeusano F, Brunetti P, et al. Two distinct MICA gene markers discriminate major autoimmune diabetes types. *J Clin Endocrinol Metab*. 2001;86(8):3754–60.
37. Berzina L, Shtauvere-Brameus A, Rumba I, and Sanjeevi CB. Microsatellite allele A5.1 of MHC class I chain-related gene A is associated with latent autoimmune diabetes in adults in Latvia. *Ann N Y Acad Sci*. 2002;958:353–6.
38. Sanjeevi CB, Kanungo A, Berzina L, Shtauvere-Brameus A, Ghaderi M, and Samal KC. MHC class I chain-related gene a alleles distinguish malnutrition-modulated diabetes, insulin-dependent diabetes, and non-insulin-dependent diabetes mellitus patients from eastern India. *Ann N Y Acad Sci*. 2002;958:341–4.
39. Torn C, Gupta M, Nikitina Zake L, Sanjeevi CB, and Landin-Olsson M. Heterozygosity for MICA5.0/MICA5.1 and HLA-DR3-DQ2/DR4-DQ8 are independent genetic risk factors for latent autoimmune diabetes in adults. *Hum Immunol*. 2003;64(9):902–9.
40. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. *Nat Immunol*. 2008;9(5):495–502.
41. Farag SS, and Caligiuri MA. Human natural killer cell development and biology. *Blood Rev*. 2006;20(3):123–37.
42. Raulet DH, Vance RE, and McMahon CW. Regulation of the natural killer cell receptor repertoire. *Annu Rev Immunol*. 2001;19:291–330.
43. Vilches C, and Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. *Annu Rev Immunol*. 2002;20:217–51.
44. Mehers KL, Long AE, van der Slik AR, Aitken RJ, Nathwani V, Wong FS, et al. An increased frequency of NK cell receptor and HLA-C group 1 combinations in early-onset type 1 diabetes. *Diabetologia*. 2011;54(12):3062–70.
45. Shastry A, Sedimbi SK, Rajalingam R, Rumba I, Kanungo A, and Sanjeevi CB. Different KIRs confer susceptibility and protection to adults with latent autoimmune diabetes in Latvian and Asian Indian populations. *Ann N Y Acad Sci*. 2008;1150:133–8.
46. Makhatadze NJ. Tumor necrosis factor locus: genetic organisation and biological implications. *Hum Immunol*. 1998;59(9):571–9.

- Accepted Article
47. Tsiavou A, Hatziagelaki E, Chaidaroglou A, Manginas A, Koniavitou K, Degiannis D, et al. TNF- α , TGF- β 1, IL-10, IL-6, gene polymorphisms in latent autoimmune diabetes of adults (LADA) and type 2 diabetes mellitus. *J Clin Immunol.* 2004;24(6):591-9.
 48. Torn C, Hillman M, Sanjeevi CB, and Landin-Olsson M. Polymorphisms of TNF microsatellite marker a and HLA-DR-DQ in diabetes mellitus—a study in 609 Swedish subjects. *Hum Immunol.* 2006;67(7):527-34.
 49. Saraiva M, Vieira P, and O'Garra A. Biology and therapeutic potential of interleukin-10. *J Exp Med.* 2020;217 (1-19).
 50. Gordon S, and Taylor PR. Monocyte and macrophage heterogeneity. *Nat Rev Immunol.* 2005;5(12):953-64.
 51. Voorbij HA, Jeucken PH, Kabel PJ, De Haan M, and Drexhage HA. Dendritic cells and scavenger macrophages in pancreatic islets of prediabetic BB rats. *Diabetes.* 1989;38(12):1623-9.
 52. Jansen A, Homo-Delarche F, Hooijkaas H, Leenen PJ, Dardenne M, and Drexhage HA. Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and beta-cell destruction in NOD mice. *Diabetes.* 1994;43(5):667-75.
 53. Walker R, Bone AJ, Cooke A, and Baird JD. Distinct macrophage subpopulations in pancreas of prediabetic BB/E rats. Possible role for macrophages in pathogenesis of IDDM. *Diabetes.* 1988;37(9):1301-4.
 54. Carrero JA, McCarthy DP, Ferris ST, Wan X, Hu H, Zinselmeyer BH, et al. Resident macrophages of pancreatic islets have a seminal role in the initiation of autoimmune diabetes of NOD mice. *Proc Natl Acad Sci U S A.* 2017;114(48):E10418-E27.
 55. Ying W, Lee YS, Dong Y, Seidman JS, Yang M, Isaac R, et al. Expansion of Islet-Resident Macrophages Leads to Inflammation Affecting beta Cell Proliferation and Function in Obesity. *Cell Metab.* 2019;29(2):457-74 e5.
 56. Mysliwska J, Smardzewski M, Marek-Trzonkowska N, Mysliwiec M, and Raczynska K. Expansion of CD14⁺CD16⁺ monocytes producing TNF- α in complication-free diabetes type 1 juvenile onset patients. *Cytokine.* 2012;60(1):309-17.
 57. Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, and Jialal I. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. *J Clin Endocrinol Metab.* 2008;93(2):578-83.
 58. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, and Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. *Diabetes.* 2006;55(3):774-9.
 59. Mollah ZU, Pai S, Moore C, O'Sullivan BJ, Harrison MJ, Peng J, et al. Abnormal NF- κ B function characterizes human type 1 diabetes dendritic cells and monocytes. *J Immunol.* 2008;180(5):3166-75.
 60. Padmos RC, Schloot NC, Beyan H, Ruwhof C, Staal FJ, de Ridder D, et al. Distinct monocyte gene-expression profiles in autoimmune diabetes. *Diabetes.* 2008;57(10):2768-73.
 61. Singh K, Martinell M, Luo Z, Espes D, Stalhammar J, Sandler S, et al. Cellular immunological changes in patients with LADA are a mixture of those seen in patients

- with type 1 and type 2 diabetes. *Clin Exp Immunol*. 2019;197(1):64-73.
62. Cejkova P, Nemeckova I, Broz J, and Cerna M. TLR2 and TLR4 expression on CD14(++) and CD14(+) monocyte subtypes in adult-onset autoimmune diabetes. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*. 2016;160(1):76-83.
63. Aida K, Fukui T, Jimbo E, Yagihashi S, Shimada A, Oikawa Y, et al. Distinct Inflammatory Changes of the Pancreas of Slowly Progressive Insulin-dependent (Type 1) Diabetes. *Pancreas*. 2018;47(9):1101-9.
64. Lopez-Castejon G, and Brough D. Understanding the mechanism of IL-1beta secretion. *Cytokine Growth Factor Rev*. 2011;22(4):189-95.
65. Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R, et al. Increased number of islet-associated macrophages in type 2 diabetes. *Diabetes*. 2007;56(9):2356-70.
66. Allen JS, Pang K, Skowera A, Ellis R, Rackham C, Lozanoska-Ochser B, et al. Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. *Diabetes*. 2009;58(1):138-45.
67. Xia CQ, Peng R, Chernatynskaya AV, Yuan L, Carter C, Valentine J, et al. Increased IFN-alpha-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-alpha production. *J Immunol*. 2014;193(3):1024-34.
68. Price JD, Beauchamp NM, Rahir G, Zhao Y, Rieger CC, Lau-Kilby AW, et al. CD8+ dendritic cell-mediated tolerance of autoreactive CD4+ T cells is deficient in NOD mice and can be corrected by blocking CD40L. *J Leukoc Biol*. 2014;95(2):325-36.
69. Price JD, Hotta-Iwamura C, Zhao Y, Beauchamp NM, and Tarbell KV. DCIR2+ cDC2 DCs and Zbtb32 Restore CD4+ T-Cell Tolerance and Inhibit Diabetes. *Diabetes*. 2015;64(10):3521-31.
70. Billiard F, Lobry C, Darrasse-Jeze G, Waite J, Liu X, Mouquet H, et al. Dll4-Notch signaling in Flt3-independent dendritic cell development and autoimmunity in mice. *J Exp Med*. 2012;209(5):1011-28.
71. Yoon JW, and Jun HS. Autoimmune destruction of pancreatic beta cells. *Am J Ther*. 2005;12(6):580-91.
72. Takahashi K, Honeyman MC, and Harrison LC. Impaired yield, phenotype, and function of monocyte-derived dendritic cells in humans at risk for insulin-dependent diabetes. *J Immunol*. 1998;161(5):2629-35.
73. Summers KL, Behme MT, Mahon JL, and Singh B. Characterization of dendritic cells in humans with type 1 diabetes. *Ann N Y Acad Sci*. 2003;1005:226-9.
74. Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S, et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. *Proc Natl Acad Sci U S A*. 2007;104(12):5115-20.
75. Willcox A, Richardson SJ, Bone AJ, Foulis AK, and Morgan NG. Analysis of islet inflammation in human type 1 diabetes. *Clin Exp Immunol*. 2009;155(2):173-81.
76. Akesson C, Uvebrant K, Oderup C, Lynch K, Harris RA, Lernmark A, et al. Altered natural killer (NK) cell frequency and phenotype in latent autoimmune diabetes in adults (LADA) prior to insulin deficiency. *Clin Exp Immunol*. 2010;161(1):48-56.
77. Wang Y, Yuan W, Guo H, and Jiang Y. High frequency of activated Nkp46(+) natural

- killer cells in patients with new diagnosed of latent autoimmune diabetes in adults. *Autoimmunity*. 2015;48(4):267-73.
78. Rodacki M, Svoren B, Butty V, Besse W, Laffel L, Benoist C, et al. Altered natural killer cells in type 1 diabetic patients. *Diabetes*. 2007;56(1):177-85.
79. Ogasawara K, Hamerman JA, Hsin H, Chikuma S, Bour-Jordan H, Chen T, et al. Impairment of NK cell function by NKG2D modulation in NOD mice. *Immunity*. 2003;18(1):41-51.
80. Diana J, and Lehuen A. Macrophages and beta-cells are responsible for CXCR2-mediated neutrophil infiltration of the pancreas during autoimmune diabetes. *EMBO Mol Med*. 2014;6(8):1090-104.
81. Harsunen MH, Puff R, D'Orlando O, Giannopoulou E, Lachmann L, Beyerlein A, et al. Reduced blood leukocyte and neutrophil numbers in the pathogenesis of type 1 diabetes. *Horm Metab Res*. 2013;45(6):467-70.
82. Valle A, Giamporcaro GM, Scavini M, Stabilini A, Grogan P, Bianconi E, et al. Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. *Diabetes*. 2013;62(6):2072-7.
83. Salami F, Lee HS, Freyhult E, Elding Larsson H, Lernmark A, Torn C, et al. Reduction in White Blood Cell, Neutrophil, and Red Blood Cell Counts Related to Sex, HLA, and Islet Autoantibodies in Swedish TEDDY Children at Increased Risk for Type 1 Diabetes. *Diabetes*. 2018;67(11):2329-36.
84. Vecchio F, Lo Buono N, Stabilini A, Nigi L, Dufort MJ, Geyer S, et al. Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. *JCI Insight*. 2018;3(18).
85. Huang J, Xiao Y, Zheng P, Zhou W, Wang Y, Huang G, et al. Distinct neutrophil counts and functions in newly diagnosed type 1 diabetes, latent autoimmune diabetes in adults, and type 2 diabetes. *Diabetes Metab Res Rev*. 2019;35(1):e3064.
86. Ji Y, Jiang D, Liu J, Chen X, Xia T, Yin Z, et al. Comparative Analysis of the Transcriptome of Latent Autoimmune Diabetes in Adult (LADA) Patients from Eastern China. *J Diabetes Res*. 2019;2019:8616373.
87. Xing Y, Lin Q, Tong Y, Zhou W, Huang J, Wang Y, et al. Abnormal Neutrophil Transcriptional Signature May Predict Newly Diagnosed Latent Autoimmune Diabetes in Adults of South China. *Front Endocrinol (Lausanne)*. 2020;11:581902.
88. Akira S, Uematsu S, and Takeuchi O. Pathogen recognition and innate immunity. *Cell*. 2006;124(4):783-801.
89. Xie Z, Huang G, Wang Z, Luo S, Zheng P, and Zhou Z. Epigenetic regulation of Toll-like receptors and its roles in type 1 diabetes. *J Mol Med (Berl)*. 2018;96(8):741-51.
90. Tai N, Wong FS, and Wen L. The role of the innate immune system in destruction of pancreatic beta cells in NOD mice and humans with type I diabetes. *J Autoimmun*. 2016;71:26-34.
91. Kim HS, Han MS, Chung KW, Kim S, Kim E, Kim MJ, et al. Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. *Immunity*. 2007;27(2):321-33.
92. Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. *J Clin Invest*. 2000;105(4):497-504.

93. Schwandner R, Dziarski R, Wesche H, Rothe M, and Kirschning CJ. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. *J Biol Chem*. 1999;274(25):17406-9.
94. Du T, Zhou ZG, You S, Lin J, Yang L, Zhou WD, et al. Regulation by 1, 25-dihydroxy-vitamin D3 on altered TLRs expression and response to ligands of monocyte from autoimmune diabetes. *Clin Chim Acta*. 2009;402(1-2):133-8.
95. Franchi L, Warner N, Viani K, and Nuñez G. Function of Nod-like receptors in microbial recognition and host defense. *Immunol Rev*. 2009;227(1):106-28.
96. Douglas R, McDonald OL. Innate Immunity. *Clinical Immunology (Fifth Edition)*. 2019:39-53. e1.
97. Kanneganti TD, Lamkanfi M, and Nunez G. Intracellular NOD-like receptors in host defense and disease. *Immunity*. 2007;27(4):549-59.
98. Li YY, Pearson JA, Chao C, Peng J, Zhang X, Zhou Z, et al. Nucleotide-binding oligomerization domain-containing protein 2 (Nod2) modulates T1DM susceptibility by gut microbiota. *J Autoimmun*. 2017;82:85-95.
99. Hu C, Ding H, Li Y, Pearson JA, Zhang X, Flavell RA, et al. NLRP3 deficiency protects from type 1 diabetes through the regulation of chemotaxis into the pancreatic islets. *Proc Natl Acad Sci U S A*. 2015;112(36):11318-23.
100. Zheng D, Liwinski T, and Elinav E. Interaction between microbiota and immunity in health and disease. *Cell Res*. 2020;30(6):492-506.
101. Belkaid Y, and Hand TW. Role of the microbiota in immunity and inflammation. *Cell*. 2014;157(1):121-41.
102. Knip M, and Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. *Nat Rev Endocrinol*. 2016;12(3):154-67.
103. Gulden E, Wong FS, and Wen L. The gut microbiota and Type 1 Diabetes. *Clin Immunol*. 2015;159(2):143-53.
104. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. *Nature*. 2008;455(7216):1109-13.
105. Giongo A, Gano KA, Crabb DB, Mukherjee N, Novelo LL, Casella G, et al. Toward defining the autoimmune microbiome for type 1 diabetes. *ISME J*. 2011;5(1):82-91.
106. Vatanen T, Franzosa EA, Schwager R, Tripathi S, Arthur TD, Vehik K, et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. *Nature*. 2018;562(7728):589-94.
107. Dunne JL, Triplett EW, Gevers D, Xavier R, Insel R, Danska J, et al. The intestinal microbiome in type 1 diabetes. *Clin Exp Immunol*. 2014;177(1):30-7.
108. de Goffau MC, Luopajarvi K, Knip M, Ilonen J, Ruotula T, Harkonen T, et al. Fecal microbiota composition differs between children with beta-cell autoimmunity and those without. *Diabetes*. 2013;62(4):1238-44.
109. Kostic AD, Gevers D, Siljander H, Vatanen T, Hyotylainen T, Hamalainen AM, et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. *Cell Host Microbe*. 2015;17(2):260-73.
110. Sorini C, Cosorich I, Lo Conte M, De Giorgi L, Facciotti F, Luciano R, et al. Loss of gut barrier integrity triggers activation of islet-reactive T cells and autoimmune diabetes. *Proc Natl Acad Sci U S A*. 2019;116(30):15140-9.

- Accepted Article
111. Eizirik DL, Colli ML, and Ortis F. The role of inflammation in insulinitis and beta-cell loss in type 1 diabetes. *Nat Rev Endocrinol*. 2009;5(4):219-26.
 112. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, and Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. *Diabetes*. 2005;54 Suppl 2:S97-107.
 113. Schloot NC, Pham MN, Hawa MI, Pozzilli P, Scherbaum WA, Schott M, et al. Inverse Relationship Between Organ-Specific Autoantibodies and Systemic Immune Mediators in Type 1 Diabetes and Type 2 Diabetes: Action LADA 11. *Diabetes Care*. 2016;39(11):1932-9.
 114. Siewko K, Maciulewski R, Zielinska-Maciulewska A, Poplawska-Kita A, Szumowski P, Wawrusiewicz-Kurylonek N, et al. Interleukin-6 and Interleukin-15 as Possible Biomarkers of the Risk of Autoimmune Diabetes Development. *Biomed Res Int*. 2019;2019:4734063.
 115. Pham MN, Hawa MI, Pflieger C, Roden M, Schernthaner G, Pozzilli P, et al. Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4. *Diabetologia*. 2011;54(7):1630-8.
 116. Xiang Y, Zhou P, Li X, Huang G, Liu Z, Xu A, et al. Heterogeneity of altered cytokine levels across the clinical spectrum of diabetes in China. *Diabetes Care*. 2011;34(7):1639-41.
 117. Sokol CL, and Luster AD. The chemokine system in innate immunity. *Cold Spring Harb Perspect Biol*. 2015;7(5).
 118. Luster AD. Chemokines--chemotactic cytokines that mediate inflammation. *N Engl J Med*. 1998;338(7):436-45.
 119. Pham MN, Hawa MI, Roden M, Schernthaner G, Pozzilli P, Buzzetti R, et al. Increased serum concentrations of adhesion molecules but not of chemokines in patients with Type 2 diabetes compared with patients with Type 1 diabetes and latent autoimmune diabetes in adult age: action LADA 5. *Diabet Med*. 2012;29(4):470-8.
 120. Nasser MW, Raghuwanshi SK, Grant DJ, Jala VR, Rajarathnam K, and Richardson RM. Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. *J Immunol*. 2009;183(5):3425-32.
 121. Deshmane SL, Kremlev S, Amini S, and Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. *J Interferon Cytokine Res*. 2009;29(6):313-26.
 122. Gorrell MD, Gysbers V, and McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. *Scand J Immunol*. 2001;54(3):249-64.
 123. Baeke F, Takiishi T, Korf H, Gysemans C, and Mathieu C. Vitamin D: modulator of the immune system. *Curr Opin Pharmacol*. 2010;10(4):482-96.
 124. Zhao Y, Yang L, Xiang Y, Liu L, Huang G, Long Z, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains beta-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. *J Clin Endocrinol Metab*. 2014;99(5):E876-80.
 125. Zhang Z, Yan X, Wu C, Pei X, Li X, Wang X, et al. Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect beta-cell function in LADA patients: A 1-year pilot study. *Diabetes Metab Res Rev*. 2020;36(5):e3298.
 126. Li X, Liao L, Yan X, Huang G, Lin J, Lei M, et al. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent

- autoimmune diabetes (LADA). *Diabetes Metab Res Rev.* 2009;25(5):411-6.
127. Buzzetti R, Pozzilli P, Frederich R, Iqbal N, and Hirshberg B. Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). *Diabetes Metab Res Rev.* 2016;32(3):289-96.
128. Johansen OE, Boehm BO, Grill V, Torjesen PA, Bhattacharya S, Patel S, et al. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. *Diabetes Care.* 2014;37(1):e11-2.
129. Pinheiro MM, Pinheiro FMM, and Trabachin ML. Dipeptidyl peptidase-4 inhibitors (DPP-4i) combined with vitamin D3: An exploration to treat new-onset type 1 diabetes mellitus and latent autoimmune diabetes in adults in the future. *Int Immunopharmacol.* 2018;57:11-7.
130. Diana J, Gahzarian L, Simoni Y, and Lehuen A. Innate immunity in type 1 diabetes. *Discov Med.* 2011;11(61):513-20.
131. Mathis D, Vence L, and Benoist C. beta-Cell death during progression to diabetes. *Nature.* 2001;414(6865):792-8.
132. Wallberg M, and Cooke A. Immune mechanisms in type 1 diabetes. *Trends Immunol.* 2013;34(12):583-91.
133. Poligone B, Weaver DJ, Jr., Sen P, Baldwin AS, Jr., and Tisch R. Elevated NF-kappaB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function. *J Immunol.* 2002;168(1):188-96.
134. Alleva DG, Pavlovich RP, Grant C, Kaser SB, and Beller DI. Aberrant macrophage cytokine production is a conserved feature among autoimmune-prone mouse strains: elevated interleukin (IL)-12 and an imbalance in tumor necrosis factor-alpha and IL-10 define a unique cytokine profile in macrophages from young nonobese diabetic mice. *Diabetes.* 2000;49(7):1106-15.
135. Uno S, Imagawa A, Okita K, Sayama K, Moriwaki M, Iwahashi H, et al. Macrophages and dendritic cells infiltrating islets with or without beta cells produce tumour necrosis factor-alpha in patients with recent-onset type 1 diabetes. *Diabetologia.* 2007;50(3):596-601.
136. Gur C, Porgador A, Elboim M, Gazit R, Mizrahi S, Stern-Ginossar N, et al. The activating receptor NKp46 is essential for the development of type 1 diabetes. *Nat Immunol.* 2010;11(2):121-8.
137. Ogasawara K, Hamerman JA, Ehrlich LR, Bour-Jordan H, Santamaria P, Bluestone JA, et al. NKG2D blockade prevents autoimmune diabetes in NOD mice. *Immunity.* 2004;20(6):757-67.
138. Laloux V, Beaudoin L, Jeske D, Carnaud C, and Lehuen A. NK T cell-induced protection against diabetes in V alpha 14-J alpha 281 transgenic nonobese diabetic mice is associated with a Th2 shift circumscribed regionally to the islets and functionally to islet autoantigen. *J Immunol.* 2001;166(6):3749-56.
139. Tang Q, and Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. *Nat Immunol.* 2008;9(3):239-44.
140. Saxena V, Ondr JK, Magnusen AF, Munn DH, and Katz JD. The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse. *J Immunol.* 2007;179(8):5041-53.

141. Lee IF, Qin H, Trudeau J, Dutz J, and Tan R. Regulation of autoimmune diabetes by complete Freund's adjuvant is mediated by NK cells. *J Immunol.* 2004;172(2):937-42.

Figure 1. Immune cells and autoimmune diabetes. The initiation of type 1 diabetes development starts with self-antigens that are released after β -cell death and are presented to $CD4^+$ T and $CD8^+$ T cells by macrophages, conventional dendritic cells (cDC), and B cells(130). The β -cell specific autoreactive $CD4^+$ T cells usually destruct β -cells by producing inflammatory cytokine IFN- γ and activating macrophages as well as dendritic cells, while $CD8^+$ T cells damage β -cells through secreting perforin/granzyme(131, 132). In addition to presenting antigens, cDCs can promote the disease development by activating T cells through producing inflammatory cytokine interleukin-12 (IL-12)(133). Macrophages also release IL-12, IL-1 β , and tumor necrosis factor- α (TNF- α) after activation(134, 135), all of which are inflammatory. Together with B-1a cells, neutrophils can initiate diabetogenic T cell response by activating plasmacytoid DCs (pDC) to produce interferon (IFN)- α (25). Natural killer (NK) cells, as important innate effector immune cells, destruct β -cell by recognizing NK cell ligand expressed on β -cell(136, 137). These pathogenic immune responses in type 1 diabetes development can be tempered by regulatory cells including IL-4 producing NKT cells(138) and regulatory T (Treg) cells(139). Additionally, cDC, pDCs and NK cells might play protective roles in disease development by expanding Treg cells(139), expressing indoleamine 2,3-dioxygenase (IDO)(140), or producing IFN- γ (141), depending on the microenvironment and insulinitis stage. For latent autoimmune diabetes in adults (LADA), $CD8^+$ T cells and macrophages are the most abundant immune cell types found in the pancreas of patients and a rat model of LADA(27, 63). In addition to these cells, $CD4^+$ T cells, B cells, and natural killer cells also infiltrate the pancreas during the development of LADA. These infiltrating immune cells were found to secrete multiple cytokines including inflammatory IFN- γ , IL-1 β , and TNF- α as well as anti-inflammatory IL-10. In comparison with type 1 diabetes, there is an increased absolute number of macrophages (which may promote the removal of apoptotic β -cells from the inflamed islets), an altered ratio of TNF- α /IL-1 β expression, and an increased expression of anti-inflammatory IL-10 in the pancreas of LADA(27). These changes may account for the slower progression of islet autoimmunity in LADA, but more studies are needed to elucidate the pathogenesis of LADA.

Table 1. Overview of circulating innate immune cell studies in patients with LADA

Cell type	Defining markers	Country	Age (Years)	Disease duration	Sample size	Alteration	Ref
Monocytes	CD16 ⁺	Sweden	65.7 ± 2.4	4.9 ± 0.3 months	13/14/16/16 (HC/LADA/T1D/T2D)	No change (vs HC, T1D, and T2D)	(61)
Dendritic cells	CD11c ⁺ DCs	Canada	37.8 ± 16.8	1.5 ± 1.3 years	7/5/9 (HC/LADA/T1D)	No change (vs HC and T1D)	(73)
	CD11c ⁻ DCs	Canada	37.8 ± 16.8	1.5 ± 1.3 years	7/5/9 (HC/LADA/T1D)	No change (vs HC and T1D)	(73)
	CD123 ⁺ CD11c ⁻ pDC	Sweden	65.7 ± 2.4	4.9 ± 0.3 months	13/14/16/16 (HC/LADA/T1D/T2D)	No change (vs HC, T1D and T2D)	(61)
	CD123 ⁻ CD11c ⁺ DCs	Sweden	65.7 ± 2.4	4.9 ± 0.3 months	13/14/16/16 (HC/LADA/T1D/T2D)	Decreased (vs T1D)	(61)
Natural killer cells	CD3 ⁻ CD16 ⁺ CD56 ⁺	Sweden	30 - 70	< 5 years	20/46 (HC/LADA)	Decreased (vs HC)	(76)
	CD3 ⁻ CD56 ^{high} CD16 ⁺	Sweden	65.7 ± 2.4	4.9 ± 0.3 months	13/14/16/16 (HC/LADA/T1D/T2D)	Increased (vs HC and T2D)	(61)
	CD3 ⁻ CD56 ⁺	China	30 - 60	< 1 month	20/27 (HC/LADA)	Increased (vs HC)	(77)
	NKp46 ⁺ NK cells	China	30 - 60	< 1 month	20/27 (HC/LADA)	Increased (vs HC)	(77)

LADA, latent autoimmune diabetes in adults; HC, healthy controls; T1D, type 1 diabetes; T2D, type 2 diabetes.

